Targeted therapies: Role of sorafenib in HCC patients with compromised liver function

Nature Reviews Clinical Oncology

Volumn 6, Issue 9, 2009, Pages 505-506

  Di Maio, Massimo ^a   Daniele, Bruno ^b   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b G RUMMO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; PLACEBO; SORAFENIB;

ADVANCED CANCER; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III AS TOPIC; FIBROSIS; HUMANS; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 70450187411     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.114     Document Type: Article

References (10)

1. Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646-649 (1973).
2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
3. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
4. Kane, R. C. et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14, 95-100 (2009).
5. Zhu, A. X. & Clark, J. W. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist 14, 67-69 (2009).
6. Abou-Alfa, G. K. et al. Is sorafenib safe and effective in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis? [abstract] ASCO Meeting Abstracts. 26, a4518 (2008).
7. Wörns, M. A. et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 43, 489-495 (2009).
8. Pinter, M. et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14, 70-76 (2009).
9. Miller, A. A. et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol. 27, 1800-1805 (2009).
10. Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008).